Tradestie Institutional Equity Comparison Engine
PACB vs PMI โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
PMI Overall Edge
PMI Captures Institutional Edge (4โ0 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Picard Medical, Inc. (PMI) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, PACB trades at N/M Forward P/E with -333.0% operating margin (+5.5% YoY revenue) versus PMI at N/M Forward P/E and -248.1% operating margin (+38.6% YoY). In options structure, PACB sits in BREAKDOWN (97th %ile IV; Dealer Gamma Walls on Pro) against PMI sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
PMI
PACB N/M vs PMI N/M Fwd P/E
Growth & Margin Winner
PMI
Op Margin -333.0% vs -248.1% ยท YoY +5.5% vs +38.6%
Momentum & Technical Winner
PMI
1Y +6.7% vs +107.2% ยท 52W Pos 29% vs 34%
Options & Structure Winner
PMI
BREAKDOWN (97th %ile IV) vs UNCLASSIFIED (N/A IV)
PACB
NASDAQ
Pacific Biosciences of California, Inc.
Laboratory Analytical Instruments
$1.76
-3.83% 1D
Market Cap
$571.4M
1M Return
-17.76%
1Y Return
+6.67%
Forward P/E
N/M
Unified AI Score
60.7 / 100
BUY
Tech 59.0
Fund 57.0
Flow 57.0
Mom 60.0
PMI
NYSE American
Picard Medical, Inc.
Surgical & Medical Instruments & Apparatus
$6.30
-2.17% 1D
Market Cap
$17.1M
1M Return
-34.58%
1Y Return
+107.24%
Forward P/E
N/M
Unified AI Score
48.4 / 100
HOLD
Tech 39.0
Fund 45.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
PACB +6.67%
PMI +107.24%
Spread: +141.36 pp (PMI Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | PACB Revenue | PMI Revenue | PACB Op. Margin | PMI Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $80M | N/A | -128.4% | N/A | PACB |
| FY2019 | $90M | N/A | -110.6% | N/A | PACB |
| FY2020 | $80M | N/A | -132.3% | N/A | PACB |
| FY2021 | $130M | N/A | -161.2% | N/A | PACB |
| FY2022 | $130M | N/A | -239.4% | N/A | PACB |
| FY2023 | $200M | N/A | -166.8% | N/A | PACB |
| FY2024 | $150M | $0M | -308.0% | -312.3% | PACB |
| FY2025 | $160M | $0M | -346.2% | -268.4% | PMI |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | PACB | PMI | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $571.4M | $17.1M | Larger Scale | PACB |
| Trailing P/E Ratio Valuation | N/M | 2.9x | Lower Multiple | PMI |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +5.5% | +38.6% | Higher Growth | PMI |
| Operating Margin (TTM) Profitability | -333.0% | -248.1% | Higher Margin | PMI |
| Net Profit Margin Profitability | -81.3% | 0.0% | Higher Margin | PMI |
| Return on Equity (ROE) Capital Efficiency | -929.3% | 0.0% | Higher ROE | PMI |
| 52-Week Range Position Momentum | 29% ($1โ$3) | 34% ($0โ$18) | Stronger Trend | PMI |
| Beta / 30D Volatility Risk Regime | 2.27ฮฒ ยท 103% Vol | 54.06ฮฒ ยท 134% Vol | Lower Realized Risk | PACB |
| Unified Institutional Score Composite Signal | 60.7 / 100 (BUY) | 48.4 / 100 (HOLD) | Higher Composite | PACB |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full PACB vs PMI Buy Guide
PACB
BREAKDOWN
15d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
97th %ile
IV Regime
Extreme (>80th %ile)
PMI
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither PACB nor PMI registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.